Clinical and Bacteriological Efficacy and Safety of 5 and 7 Day Regimens of Telithromycin Once Daily Compared With a 10 Day Regimen of Clarithromycin Twice Daily In …
Manish Patel
Journal of …, 2004
View PDFchevron_right
Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis
c fogarty
Respiratory Medicine, 2003
View PDFchevron_right
Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia
Manickam Rangaraju
Respiratory Medicine, 2006
View PDFchevron_right
Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae
Fiona Walsh
2004
View PDFchevron_right
Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study
c fogarty
BMC infectious diseases, 2005
View PDFchevron_right
Efficacy of Telithromycin in Community-Acquired Pneumonia Caused by Pneumococci with Reduced Susceptibility to Penicillin and/or Erythromycin
Manickam Rangaraju
Chemotherapy, 2005
View PDFchevron_right
Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003–2004)
Francesco Blasi
Diagnostic Microbiology and Infectious Disease, 2009
View PDFchevron_right
Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis
Antonio Anzueto
2005
View PDFchevron_right
Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae
Maria Salvo
Journal of Infection, 2005
View PDFchevron_right
Pharmacodynamics of Telithromycin In Vitro against Respiratory Tract Pathogens
Inga Odenholt
Antimicrobial Agents and Chemotherapy, 2001
View PDFchevron_right
Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia
manish patel
2004
View PDFchevron_right
Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review
Manickam Rangaraju
International Journal of Infectious Diseases, 2006
View PDFchevron_right
In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis
Zerrin Aktas
International Journal of Antimicrobial Agents, 2003
View PDFchevron_right
Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations
Ayman Noreddin
Journal of Antimicrobial Chemotherapy, 2004
View PDFchevron_right
Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens
Ellie Goldstein
International Journal of Antimicrobial Agents, 2007
View PDFchevron_right
Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia
Manickam Rangaraju
Clinical Microbiology and Infection, 2003
View PDFchevron_right
Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin
George Drusano
Clinical Microbiology and Infection, 2008
View PDFchevron_right
In vitro activity of telithromycin against Haemophilus influenzae at epithelial lining fluid concentrations
Elena Vecchi
BMC Microbiology, 2008
View PDFchevron_right
Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides
Maria R Gismondo
Journal of Antimicrobial Chemotherapy, 2004
View PDFchevron_right
Comparative pharmacodynamics of telithromycin and clarithromycin with and in an in vitro dynamic model: focus on clinically achievable antibiotic concentrations
Irene Lubenko
International Journal of Antimicrobial Agents, 2005
View PDFchevron_right
Comparative pharmacodynamics of telithromycin and clarithromycin with Streptococcus pneumoniae and Staphylococcus aureus in an in vitro dynamic model: focus on clinically achievable antibiotic concentrations
Irene Lubenko
International Journal of Antimicrobial Agents, 2005
View PDFchevron_right
In Vitro Activity of Telithromycin against Spanish Streptococcus pneumoniae Isolates with Characterized Macrolide Resistance Mechanisms
María-isabel Morosini
Antimicrobial Agents and Chemotherapy, 2001
View PDFchevron_right
Influence of Carbon Dioxide on the MIC of Telithromycin for Streptococcus pneumoniae: an In Vitro-In Vivo Study
Cédric Jacqueline
Antimicrobial Agents and Chemotherapy, 2005
View PDFchevron_right
Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days
Bruce Lavin
Current Medical Research and Opinion, 2004
View PDFchevron_right
Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials
Bruce Lavin
Current Medical Research and Opinion, 2004
View PDFchevron_right
Activity of telithromycin and seven other agents against 1034 pediatric Streptococcus pneumoniae isolates from ten central and eastern European centers
Marina Pană
Clinical Microbiology and Infection, 2003
View PDFchevron_right